The pandemic outbreak of the influenza opened the gates for the drugs such as Tamiflu in the initial phase for the curing of the disease but the following phase will see a shift from curing to prevention.  Thus, arise the requirement for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast for the upcoming vaccines for the prevention of the disease among the unaffected population. The vaccines market is classified for the intramuscular vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market revenues and the remaining will be tapped by the intranasal vaccines. The initial lot of vaccines will be of egg based and cell based manufacturing. The market forecast is from late 2009 as the first lot of doses are expected to be rolled out in the first week of October 2009.

The first movers of the in the vaccines market are Glaxo Smith Kline (GSK), Novartis, CSL, Medimmune, Baxter, Sinovec and Sanofi Pastuer. Medimmune is the only producer of the intranasal vaccine whereas other companies are expected to come out with intramuscular vaccines. The companies have got approvals for their first lots from the governments of the various countries such as U.S., U.K., France, China, Denmark and Australia. The involvement of government bodies, increased awareness about prevention and pandemic situation of the influenza is driving the market for the vaccines.

Due to intensive ongoing research and technology introduction, the market players are compelled to understand the market dynamics, innovations,  pricing, products, marketing and regulatory framework of the market.

The global H1N1 Influenza vaccine market is estimated to be of 676 million in 2009 with first lot of doses being commercialized on 30th September’ 2009. The market will see a high CAGR for the next two years i.e. the market is expected to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011. However, the very high CAGR will settle down by 2012 to 30% for the period of 2009 to 2012. The reason for the sudden settle down of the growth is that it is expected that most of the world population will be immunized by the end of 2011.

MarketsandMarkets, a research and consulting firm now onto publishing, is producing high level strategically analyzed 250 page reports about 120 a year. Worldwide, market research reports are primarily sold for numbers, market segmentation and competitive landscape, within the business leaders. MarketsandMarkets reports are equipped with more than 100+ market data summary tables, in-depth segmentation up to level 5 for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports of about 250 pages analyze about 200 patents, over 50 companies and micro markets which are collectively exhaustive but mutually exclusive. The analyst working with MarketsandMarkets come from the renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a database of hundred thousand of key industry participants and draw on our relationship with more than 900 market research companies globally. We, at MarketsandMarkets, are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our report, please visit our website (www.marketsandmarkets.com)

Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your successful registration.